Xeris Pharmaceuticals is a specialty pharmaceutical company that develops and commercializes ready-to-use injectable and infusible drug formulations. The company's proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly concentrated, non-aqueous, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. Xeris' lead product, Gvoke HypoPen, is the first ready-to-use glucagon injection for the treatment of severe hypoglycemia in diabetes patients. The company is also developing a pipeline of other ready-to-use injectable and infusible drug formulations for various indications, including epilepsy, hypoglycemia, and post-operative pain management.